A clinical case report in Annals of Hematology describes a relapsed acute myeloid leukemia patient who achieved complete remission lasting more than five years after a switch in FLT3-directed therapy driven by serial molecular profiling. The report highlights emergence of an FLT3-D835V resistance mutation during quizartinib maintenance and subsequent response to gilteritinib, underscoring the value of time-resolved genotyping to guide salvage and maintenance strategies.